Clinical trials: Tocilizumab
Systemic Lupus Erythematosus, Idiopathic Inflammatory Myopathy
A Study of CC-97540, CD-19-Targeted Nex-T CAR T Cells, in Participants With Severe, Refractory Autoimmune Diseases (Breakfree-1)
The purpose of this study is to establish the tolerability, preliminary efficacy, and pharmacokinetics of CC-97540 in participants with severe, refractory autoimmune diseases (Breakfree-1).
- Conditions
- Systemic Lupus Erythematosus, Idiopathic Inflammatory Myopathy, Systemic Sclerosis, Rheumatoid Arthritis
- Trial name
- NCT05869955
- Testing
- CC-97540, Fludarabine, Cyclophosphamide
- Where
- 46 sites in United States, Belgium and 4 more
- Volunteers
- 270 people
- Sponsor
- Juno Therapeutics, Inc., a Bristol-Myers Squibb Company
Juvenile Idiopathic Arthritis
A Study of Tocilizumab in Patients With Active Polyarticular Juvenile Idiopathic Arthritis
This 3-part study evaluated the efficacy and safety of tocilizumab in patients with active polyarticular-course juvenile idiopathic arthritis who have an inadequate response to, or were intolerant of methotrexate.
- Trial name
- NCT00988221
- Testing
- Tocilizumab
- Where
- 69 sites in United States, Argentina and 13 more
- Volunteers
- 188 people
- Sponsor
- Hoffmann-La Roche
Rheumatoid Arthritis
A Study of RoActemra/Actemra (Tocilizumab) Plus DMARDs in Patients With Rheumatoid Arthritis
This open-label study will evaluate the long-term safety and efficacy of RoActemra/Actemra (tocilizumab) in combination with disease modifying anti-rheumatic drugs (DMARDs) in patients with moderate to severe rheumatoid…
- Trial name
- NCT01214733
- Testing
- tocilizumab [RoActemra/Actemra]
- Where
- 4 sites in South Africa
- Volunteers
- 30 people
- Sponsor
- Hoffmann-La Roche
Juvenile Idiopathic Arthritis
Study of Oral Upadacitinib and Subcutaneous/Intravenous Tocilizumab to Evaluate Change in Disease Activity, Adverse Events and How Drug Moves Through the Body of Pediatric and Adolescent Participants With Active Systemic Juvenile Idiopathic Arthritis.
Juvenile Idiopathic Arthritis (JIA) is the most common type of arthritis that affects children. The term "idiopathic" means "of unknown origin".
- Trial name
- SELECT-sJIA (NCT05609630)
- Testing
- Upadacitinib, Tocilizumab
- Where
- 45 sites in United States, Argentina and 15 more
- Volunteers
- 90 people
- Sponsor
- AbbVie
Interstitial Lung Diseases, Systemic Sclerosis Associated Interstitial Lung Disease
A Study Using a Disease Registry to Observe the Long-term Effects of Nintedanib in People With Scleroderma-related Lung Fibrosis
This post-approval registry study is planned to generate data to address remaining questions on long-term effectiveness and to better characterize longer term beneficial effects of Nintedanib in patients with systemic sclerosis…
- Trial name
- NCT07080125
- Testing
- Ofev®
- Where
- Switzerland
- Volunteers
- 2,000 people
- Sponsor
- Boehringer Ingelheim
Giant Cell Arteritis
An Efficacy and Safety Study of Tocilizumab (RoActemra/Actemra) in Participants With Giant Cell Arteritis (GCA)
This multicenter, randomized, double-blind, placebo-controlled, parallel-group study will evaluate the efficacy and safety of tocilizumab in participants with GCA.
- Trial name
- NCT01791153
- Testing
- Tocilizumab, Prednisone, Corticosteroids
- Where
- 78 sites in United States, Belgium and 12 more
- Volunteers
- 251 people
- Sponsor
- Hoffmann-La Roche
Healthy Men
A Randomized, Double-blind, Single-dose, Two-arm Parallel Study to Compare the Pharmacokinetics and Safety of BAT1806 Prefilled Subcutaneous Injection With RoActemra® in Healthy Chinese Male Subjects
This is a randomized, double-blind, single-dose, two-arm parallel study to compare the pharmacokinetics, safety and immunogenicity of BAT1806 prefilled subcutaneous injection with RoActemra® (from EU) in healthy male subjects.
- Trial name
- NCT05968508
- Testing
- BAT1806 prefilled subcutaneous injection/RoActemra® (from EU)
- Where
- China
- Volunteers
- 300 people, healthy volunteers welcome
- Sponsor
- Bio-Thera Solutions
Rheumatoid Arthritis
Single-dose Study to Describe the Pharmacodynamics (PD) and Safety of Sarilumab (REGN88/SAR153191) and Tocilizumab in Adults With Rheumatoid Arthritis (RA)
The main purposes of this study are to describe the pharmacodynamic effects, safety and pharmacokinetics of a single dose of sarilumab.
- Trial name
- NCT02097524
- Testing
- Sarilumab, Tocilizumab
- Where
- 19 sites in United States
- Volunteers
- 105 people
- Sponsor
- Regeneron Pharmaceuticals
Rheumatoid Arthritis
An Observational Study of RoActemra/Actemra (Tocilizumab) As Monotherapy in Rheumatoid Arthritis Patients in Routine Clinical Practice
This prospective, multi-center, observational study will evaluate factors influencing the use of tocilizumab (RoActemra/Actemra) as monotherapy in rheumatoid arthritis patients in real life setting.
- Trial name
- ACT SOLO (NCT01474291)
- Testing
- Tocilizumab
- Where
- 119 sites in France
- Volunteers
- 608 people
- Sponsor
- Hoffmann-La Roche
Rheumatoid Arthritis
An Observational Study of RoActemra/Actemra (Tocilizumab) in Smoking Versus Non-Smoking Patients With Rheumatoid Arthritis
This observational study will assess the efficacy and safety of RoActemra/Actemra (Tocilizumab) in smoking versus non-smoking patients with rheumatoid arthritis.
- Trial name
- NCT01337388
- Where
- 29 sites in Norway, Sweden
- Volunteers
- 197 people
- Sponsor
- Hoffmann-La Roche
Spondylitis, Ankylosing
A Study of Tocilizumab (RoActemra/Actemra) in Patients With Ankylosing Spondylitis Who Have Had an Inadequate Response to Previous Tumor Necrosis Factor (TNF) Antagonist Therapy
This randomized, double-blind, placebo-controlled study evaluated the safety and efficacy of tocilizumab (RoActemra/Actemra) in patients with ankylosing spondylitis (AS) who had an inadequate response to previous tumor necrosis…
- Trial name
- NCT01209689
- Testing
- Tocilizumab
- Where
- 140 sites in United States, Australia and 17 more
- Volunteers
- 113 people
- Sponsor
- Hoffmann-La Roche
Rheumatoid Arthritis
A Study Assessing the Safety and Efficacy of Subcutaneous RoActemra/Actemra Alone or in Combination With Non-biologic Antirheumatics in Rhuematoid Arthritis Patients in Latin America With Inadequate Response to Non-biologic Antirheumatic Drugs.
This multi-center, open-label, single-arm, Phase IIIb study will evaluate the safety and efficacy of subcutaneous RoActemra/Actemra alone or in combination with non-biologic disease modifying antirheumatic drugs (DMARDs) in…
- Trial name
- NCT02011334
- Testing
- tocilizumab [RoActemra/Actemra]
- Where
- 25 sites in Argentina, Brazil and 4 more
- Volunteers
- 285 people
- Sponsor
- Hoffmann-La Roche
Rheumatoid Arthritis
A Study of Tocilizumab Added to DMARDs in Patients With Moderate to Severe Rheumatoid Arthritis and an Inadequate Response to DMARDs.
This open-label single arm study will evaluate the efficacy and safety of tocilizumab added to traditional disease-modifying antirheumatic drugs (DMARDs) in patients with moderate to severe active rheumatoid arthritis and an…
- Trial name
- NCT00996203
- Testing
- tocilizumab [RoActemra/Actemra], DMARDs (disease-modifying antirheumatic drugs)
- Where
- 28 sites in Russia
- Volunteers
- 201 people
- Sponsor
- Hoffmann-La Roche
Rheumatoid Arthritis
A Long Term Extension Study of WA19926 (NCT01007435) of Tocilizumab (RoActemra/Actemra) in Participants With Early, Moderate to Severe Rheumatoid Arthritis (RA)
This open-label, single arm, multicenter long-term extension study of WA19926 (NCT01007435) will evaluate the safety and efficacy of tocilizumab in participants with early, moderate to severe RA who have completed the 104-week…
- Trial name
- NCT01668966
- Testing
- Tocilizumab
- Where
- 6 sites in Brazil
- Volunteers
- 23 people
- Sponsor
- Hoffmann-La Roche
Rheumatoid Arthritis
Real World Use of Tocilizumab Biosimilar studY
The goal of this non interventional study is to evaluate the use of Tyenne, a tocilizumab biosimilar, in a real world setting in Rheumatoid Arthritis (RA) patients over a period of 12 months.
- Trial name
- RUBY (NCT06247722)
- Where
- 8 sites in Germany
- Volunteers
- 600 people
- Sponsor
- Fresenius Kabi SwissBioSim GmbH
Rheumatoid Arthritis
A Study of RoActemra/Actemra (Tocilizumab) in Patients With Active Rheumatoid Arthritis Who Have an Inadequate Response to DMARDs (REMISSION)
This open label, single arm study will assess the safety and efficacy of RoActemra/Actemra (tocilizumab) in patients with moderate to severe active rheumatoid arthritis who have an inadequate response to disease-modifying…
- Trial name
- NCT01610791
- Testing
- tocilizumab [RoActemra/Actemra]
- Where
- 8 sites in Morocco
- Volunteers
- 121 people
- Sponsor
- Hoffmann-La Roche
Refractory Cancer, Recurrent Cancer
A Study of RO7617991 in Patients With Locally Advanced or Metastatic MAGE-A4-Positive Solid Tumors
This study will evaluate the safety, tolerability, and pharmacokinetics of RO7617991, and will make a preliminary assessment of the anti-tumor activity of RO7617991 in human leukocyte antigen (HLA)-A*02 eligible patients with…
- Conditions
- Refractory Cancer, Recurrent Cancer, Solid Tumor, Adult
- Trial name
- NCT06372574
- Testing
- RO7617991, Tocilizumab
- Sponsor
- Genentech, Inc.
Healthy Volunteer
A Study to Evaluate the Bioequivalence of Tocilizumab Following Subcutaneous Administration Via an Autoinjector (AI 1000-G2) Versus a Pre-Filled Syringe in Healthy Volunteers
The study consists of an eligibility screening period, two study periods involving single doses of tocilizumab (TCZ) according to an open-label, randomized, two-period crossover design with an interval of 6 weeks between periods…
- Trial name
- NCT02678988
- Testing
- AI-1000 G2, PFS-NSD, Tocilizumab
- Where
- 3 sites in United States
- Volunteers
- 189 people, healthy volunteers welcome
- Sponsor
- Hoffmann-La Roche
Castleman's Disease
A Study to Provide RoActemra/Actemra (Tocilzumab) to Patients With Multicentric Castleman's Disease Who Demonstrated Benefit From Previous RoActemra/Actemra Treatment
This open-label, single center study will provide RoActemra/Actemra (tocilizumab) to a maximum of 4 patients with Multicentric Castelman's Disease who have demonstrated benefit from RoActemra/Actemra in study MRA004US (Chugai…
- Trial name
- NCT01183598
- Testing
- tocilizumab [RoActemra/Actemra]
- Where
- United States
- Volunteers
- 3 people
- Sponsor
- Hoffmann-La Roche
Multiple Myeloma
A Study Evaluating the Pharmacokinetics, Safety, and Efficacy of Cevostamab in Chinese Participants With Relapsed or Refractory Multiple Myeloma
This study will evaluate the pharmacokinetics (PK), safety, and efficacy of cevostamab in participants with relapsed or refractory (R/R) multiple myeloma (MM).
- Trial name
- NCT06934044
- Testing
- Cevostamab, Tocilizumab
- Where
- 5 sites in China
- Volunteers
- 20 people
- Sponsor
- Hoffmann-La Roche